利拉鲁肽对2型糖尿病患者血内脏脂肪素、瘦素及胰岛素抵抗的影响分析  

Analysis of the Effect of Liraglutide on Blood Visfatin,Leptin and Insulin Resistance in Patients with Type 2 Diabetes Mellitus

作　　者：胡玉娟[1] 王尉[2] 徐延德 HU Yujuan;WANG Wei;XU Yande(Outpatient Pharmacy,Jinan Fifth People's Hospital,Jinan,Shandong Province,250000 China;Ward Pharmacy,Jinan Fifth People's Hospital,Jinan,Shandong Province,250000 China)

机构地区：[1]济南市第五人民医院门诊药房,山东济南250000 [2]济南市第五人民医院病房药房,山东济南250000

出　　处：《系统医学》2022年第14期58-62,共5页Systems Medicine

摘　　要：目的 利拉鲁肽在2型糖尿病(T2DM)患者中应用价值。方法 选取于2020年8月—2021年12月到济南市第五人民医院接受治疗的128例T2DM患者为研究对象,采用数字随机分配原则分为对照组(n=64)和观察组(n=64),分别选择西格列汀和利拉鲁肽治疗。对比两组血糖、脂质、胰岛素抵抗、常规体检指标、不良反应及不同病程T2DM患者接受利拉鲁肽治疗后BMI、血糖的情况。结果 治疗前,两组血糖、脂质水平、胰岛素抵抗情况、体质量、体质指数(BMI)对比,差异无统计学意义(P>0.05);治疗后,观察组空腹血糖(FPG)、餐后2 h血糖(2 hPG)、糖化血红蛋白(HbA1c)水平分别为(6.23±0.39)mmol/L、(8.41±0.68)mmol/L、(6.11±1.67)%,低于对照组,差异有统计学意义(t=2.716、2.924、3.367,P<0.05);观察组胆固醇(TC)、脂肪素、血清瘦素(Lp)分别为(4.06±1.11)mmol/L、(39.24±9.58)ng/mL、(3.15±1.26)μg/L,低于对照组,差异有统计学意义(t=2.884、3.004、3.082,P<0.05),两组三酰甘油(TG)、低密度脂蛋白(LDL-C)、高密度脂蛋白胆(HDL-C)对比,差异无统计学意义(P>0.05)。观察组空腹胰岛素(FINS)水平,胰岛素抵抗指数(HOMA-IR)分别为(9.23±3.58)IU/L、(2.48±1.01),低于对照组,差异有统计学意义(t=2.770、4.381,P<0.05)。观察组体质量、BMI分别为(64.02±6.57)kg、(23.71±2.57)kg/m~2,低于对照组,差异有统计学意义(t=3.024、5.789,P<0.05)。观察组不良反应发生率为7.81%,对照组不良反应发生率15.63%,但差异无统计学意义(χ^(2)=1.888,P>0.05);治疗24周后,病程≤5年患者的FPG、2 hPG、BMI分别为(6.33±0.25)mmol/L、(8.67±0.48)mmol/L、(23.21±1.89)kg/m~2,低于病程>5年患者,差异有统计学意义(t=2.122、2.576、2.301,P<0.05)。结论 利拉鲁肽对T2DM患者降低血糖的效果好,能够有效改善胰岛素抵抗,降低内脏脂肪素和Lp水平,减轻体质量、BMI,且安全性高;糖尿病早期开始选用利拉鲁肽治疗,降糖,改善胰岛素功能的效果更为�Objective To evaluate the application value of liraglutide in patients with type 2 diabetes mellitus(T2DM).Methods A total of 128 T2DM patients who received treatment in Jinan Fifth People’s Hospital from August 2020 to December 2021 were selected as the research subjects.The patients were divided into the control group(n=64) and the observation group(n=64) according to the principle of digital random assignment,and they were treated with sitagliptin and liraglutide respectively.The blood glucose,lipids,insulin resistance,routine physical examination indicators,adverse reactions,and BMI and blood glucose after liraglutide treatment were compared between the two groups of T2DM patients.Results Before treatment,there was no significant difference in blood glucose,lipid levels,insulin resistance,body weight and body mass index(BMI) between the two groups(P>0.05).After treatment,the levels of fasting blood glucose(FPG),two-hour postprandial blood glucose(2 hPG),and glycosylated hemoglobin(HbA1c) in the observation group were(6.23±0.39) mmol/L,(8.41±0.68) mmol/L,and(6.11±1.67)%,lower than the control group.The difference was statistically significant(t=2.716,2.924,3.367,P<0.05).The cholesterol(TC),lipotin and serum leptin(Lp) in the observation group were(4.06±1.11) mmol/L,(39.24±9.58) ng/mL,(3.15±1.26) μg/L,respectively,which were lower than those in the control group.The difference was statistically significant(t=2.884,3.004,3.082,P<0.05).The comparison of triglyceride(TG),low density lipoprotein(LDL-C) and high density lipoprotein cholesterol(HDL-C) between the two groups,the difference was not statistically significant(P>0.05).The levels of fasting insulin(FINS) and insulin resistance index(HOMA-IR) in the observation group were(9.23±3.58) IU/L and(2.48±1.01),respectively,which were lower than those in the control group,and the differences were statistically significant(t=2.770,4.381,P<0.05).The body weight and body mass index(BMI) of the observation group were(64.02±6.57) kg and(23.71±2.57) kg/m~2,re

关 键 词：利拉鲁肽 2型糖尿病 血内脏脂肪素 瘦素 胰岛素抵抗 体质指数 

分 类 号：R587.1[医药卫生—内分泌]